Phase 1b/2a Program Commences for RVX-208
News Aug 26, 2008
RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production. Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix stated "We are very excited about moving forward into this important 28-daystudy with RVX-208. Our previous clinical study demonstrated that RVX-208 was safe, tolerable and had favorable pharmacokinetics,"
"This trial will continue to examine safety and tolerance as well it is a proof of principle study for ApoA-I production and HDL functionality. Approximately half of the subjects will have low levels of HDL cholesterol, a condition associated with
significant increased risk of cardiovascular disease," added Dr. Gordon.
"The ensuing Phase 1b/2a study comprises several novel facets to expedite
the clinical process for RVX-208 and its eventual registration as a drug,"
stated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey
further confirmed, "Along with the required regulatory provisions that must be
addressed such as safety, tolerance and pharmacokinetics, the study also will
measure key reverse cholesterol transport markers which RVX-208 impacts. These are exclusive favorable features that make this drug unique among its
RVX-208 is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase
ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE